2025 Year in Review

Looking back at 2025, we’re incredibly humbled to reflect on a year of meaningful growth and deepened partnerships at Miracle. Over the past year, our platform continued to support an expanding number of clinical studies across multiple therapeutic areas, helping biopharma teams operate with greater confidence, clarity, and control as their clinical trials scaled.

Clinical development and operations remain among the most complex and high-stakes endeavors in drug development. As studies grow larger and more global, teams face increasing pressure to manage fragmented data, coordinate across internal functions and external vendors, and identify issues and risks before they impact timelines.

This past year, our focus was on helping clinical teams move from reactive oversight to proactive trial management, ensuring that critical decisions are informed by timely, trustworthy insights.

Below are a few key themes that defined how we supported our biopharma partners in 2025.

Scaling Real-Time Visibility Across Active Trials

As our customers’ pipelines expanded, so did the complexity of their clinical trial management and clinical operations. In 2025, Miracle helped clinical teams maintain real-time visibility across enrollment, data entry, protocol deviations, and study milestones, even as the number of studies, sites, vendors, and even countries increased.

By consolidating operational signals into a single source of truth and eliminating numerous spreadsheet trackers, teams were able to quickly identify emerging risks and address them early, rather than discovering issues days, if not weeks, later during routine reviews.

In our customers’ words:

“Our team has been able to drastically reduce manual tracking thereby allowing us to focus on protocol adherence, patient management, predict potential study bottlenecks and scalability.”
– Senior Director, Clinical Operations

Delivering the Right Level of Visibility for Every Role

Different stakeholders require different levels of insight to perform their roles effectively. In 2025, Miracle helped clinical operations, data management, medical, safety, and leadership teams access the appropriate signals most relevant to their responsibilities, while minimizing noise.

By enabling role-appropriate views into trial operations, teams aligned more effectively, reduced back-and-forth across functions, and focused their time on resolving the most critical issues faster.

Customer Highlight:

“With its ease of use, Miracle has proven invaluable to all functional areas across our team.”
– Chief Medical Officer

Moving Beyond Dashboards to Actionable Insights

While dashboards are essential, they are only valuable if they drive meaningful action that impact clinical operations. This past year, Miracle helped teams move beyond static views by surfacing actionable insights that span multiple clinical trial systems.

By unifying data across platforms such as EDC, IRT, and other study platforms, teams were able to identify meaningful patterns and risks that would have been difficult to detect in isolation, allowing for earlier intervention and more informed decision-making.

You can check out our two-part series on centralized, real-time alerts (link) for more information.

What our partners shared:

“We can integrate real-time metrics and alerts into a single platform which allows us to consolidate visibility, intervene proactively with our vendors, and accelerates our decision-making capability.”
– Head of Clinical Operations

Extending Insight from the Study Level to the Portfolio Level

As development pipelines grow, sponsors increasingly need to understand what’s happening not only within individual studies, but across their broader clinical portfolio. In 2025, Miracle helped teams analyze operational trends across multiple studies, independent of the underlying trial systems in use, enabling leadership to identify shared risk patterns and critical signals at the portfolio level.

This unified view supported more strategic planning and allowed teams to apply lessons learned from one study to others across therapeutic areas, strengthening execution consistency across the portfolio.

From our biopharma partners:

“We used to update these trackers every 2-3 weeks because it took hours. Now I just pull up Miracle.”
– Director, Clinical Operations

Trusted by Teams Across Therapeutic Areas

Throughout the entire year, Miracle continued to support studies across a wide range of indications, including CNS, rare diseases, cardiovascular diseases, and more. Regardless of indication, the underlying challenge remained the same: turning fragmented trial data from systems such as EDC, IRT, ePRO/eCOA, and labs into clear, actionable operational insight.

We’re deeply grateful for the trust our partners place in us to support their most critical development programs.

Customer Highlight:

"We went from raw datasets to interactive visualizations quickly. The platform handled the complex logic… and let us iterate quickly.”
– Senior Director, Medical Affairs

Looking Ahead

As we move into the coming year, our focus remains unchanged: helping biopharma teams run smarter, more efficient clinical trials. We’re excited to continue working closely with our partners to further refine how operational data is surfaced, interpreted, and acted upon, all with the shared urgency of bringing new treatments to patients faster.

As some of our customers move closer to FDA approval, it has been especially rewarding to support their teams in saving meaningful time in clinical operations and contributing to the delivery of new therapies to patients.

To our customers and partners: thank you for your collaboration, feedback, and trust. We’re honored to support your teams and the important therapies you’re developing.

Here’s to another year of innovation in clinical trials.

‍